sj-tif-4-tae-10.1177_20420188221122426 – Supplemental material for Metabolic benefits of changing sedentary lifestyles in nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials

Supplemental material, sj-tif-4-tae-10.1177_20420188221122426 for Metabolic benefits of changing sedentary lifestyles in nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials by Qianqian Ma, Junzhao Ye, Congxiang Shao, Yansong Lin, Tingfeng Wu and Bihui Zhong in Therapeutic Advances in Endocrinology and Metabolism</p

sj-tif-3-tae-10.1177_20420188221122426 – Supplemental material for Metabolic benefits of changing sedentary lifestyles in nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials

Supplemental material, sj-tif-3-tae-10.1177_20420188221122426 for Metabolic benefits of changing sedentary lifestyles in nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials by Qianqian Ma, Junzhao Ye, Congxiang Shao, Yansong Lin, Tingfeng Wu and Bihui Zhong in Therapeutic Advances in Endocrinology and Metabolism</p

sj-tif-1-tae-10.1177_20420188221122426 – Supplemental material for Metabolic benefits of changing sedentary lifestyles in nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials

Supplemental material, sj-tif-1-tae-10.1177_20420188221122426 for Metabolic benefits of changing sedentary lifestyles in nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials by Qianqian Ma, Junzhao Ye, Congxiang Shao, Yansong Lin, Tingfeng Wu and Bihui Zhong in Therapeutic Advances in Endocrinology and Metabolism</p

sj-tif-5-tae-10.1177_20420188221122426 – Supplemental material for Metabolic benefits of changing sedentary lifestyles in nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials

Supplemental material, sj-tif-5-tae-10.1177_20420188221122426 for Metabolic benefits of changing sedentary lifestyles in nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials by Qianqian Ma, Junzhao Ye, Congxiang Shao, Yansong Lin, Tingfeng Wu and Bihui Zhong in Therapeutic Advances in Endocrinology and Metabolism</p

sj-tif-2-tae-10.1177_20420188221122426 – Supplemental material for Metabolic benefits of changing sedentary lifestyles in nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials

Supplemental material, sj-tif-2-tae-10.1177_20420188221122426 for Metabolic benefits of changing sedentary lifestyles in nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials by Qianqian Ma, Junzhao Ye, Congxiang Shao, Yansong Lin, Tingfeng Wu and Bihui Zhong in Therapeutic Advances in Endocrinology and Metabolism</p

Enhancer of Zeste Homolog 2 as an Independent Prognostic Marker for Cancer: A Meta-Analysis

<div><p>Background</p><p>Novel biomarkers are of particular interest for predicting cancer prognosis. This study aimed to explore the associations between enhancer of zeste homolog 2 (EZH2) and patient survival in various cancers.</p><p>Methods</p><p>Relevant literature was retrieved from PubMed and Web of Science databases. Pooled hazard ratios (HRs), odds ratios (ORs), and 95% confidence intervals (CIs) were calculated.</p><p>Results</p><p>Forty-nine studies (8,050 patients) were included. High EZH2 expression was significantly associated with shorter overall (hazard ratio [HR] 1.74, 95% CI: 1.46–2.07), disease-free (HR 1.59, 95% CI: 1.27–1.99), metastasis-free (HR 2.19, 95% CI: 1.38–3.47), progression-free (HR 2.53, 95% CI: 1.52–4.21), cancer-specific (HR 3.13, 95% CI: 1.70–5.74), and disease-specific (HR 2.29, 95% CI: 1.56–3.35) survival, but not recurrence-free survival (HR 1.38, 95% CI: 0.93–2.06). Moreover, EZH2 expression significantly correlated with distant metastasis (OR 3.25, 95% CI: 1.07–9.87) in esophageal carcinoma; differentiation (OR 3.00, 95% CI: 1.37–6.55) in non-small cell lung cancer; TNM stage (OR 3.18, 95% CI: 2.49–4.08) in renal cell carcinoma; and histological grade (OR 4.50, 95% CI: 3.33–6.09), estrogen receptor status (OR 0.15, 95% CI: 0.11–0.20) and progesterone receptor status (OR 0.30, 95% CI: 0.23–0.39) in breast cancer.</p><p>Conclusions</p><p>Our results suggested that EZH2 might be an independent prognostic factor for multiple survival measures in different cancers.</p></div

Schemata of the systematic review.

<p>Schemata of the systematic review.</p

Meta analysis of the independent role of <i>HOTAIR</i> in OS/recurrence/metastasis of different types of cancer.

<p>Meta analysis of the independent role of <i>HOTAIR</i> in OS/recurrence/metastasis of different types of cancer.</p

Characteristics of studies included in the meta-analysis.

<p>SI (staining index score): staining intensity x proportion of positively stained cells. OS: overall survival. DFS: disease free survival. MFS: metastasis free survival. LRFS: local recurrence free survival. DMFS: distant metastasis free survival.</p><p>EI: expression index, it was calculated from the formula 1,000 9 2(-DCt), where DCt = Ct (HOTAIR) - Ct (GAPDH). NA: not available.</p><p>*1 denoted as obtaining HRs directly from publications; 2 denoted as calculating HRs from the total number of events and its <i>p</i>-value; 3 denoted as extracting HRs from Kaplan-Meier curves.</p><p>Characteristics of studies included in the meta-analysis.</p

Meta analysis of the pooled HRs of OS of different types of cancer with increased <i>HOTAIR</i> expression.

<p>(A) Subgroup analysis of HRs of OS by factor of region. (B) Subgroup analysis of HRs of OS by factor of score. (C) Subgroup analysis of HRs of OS by factor of sample size. (D) Subgroup analysis of HRs of OS by factor of type of cancer.</p